This graphic shows a list of which studies have been halted by eliminated USAID funding.
Multipurpose Prevention Technologies (MPTs) Studies Halted by USAID Funding Termination
At A Glance: The MPT R&D Pipeline
This graphic shows the status of products in development.
People’s Research Agenda Pipeline Tracker
This tracker provides details on key HIV prevention trials to watch. It is updated on a quarterly and ad-hoc basis as developments occur.
If you would like to share additional information or corrections, please email Breanne at [email protected]. For more, visit the People’s Research Agenda.
Spotlight on MPTs Addressing STIs
This graphic outlines the development journey of multipurpose technologies (MPTs) that guard against STIs, including HIV, while also preventing pregnancy. It tracks the advancement of various potential products through different trial stages, emphasizing their combined protective roles.
PrEP Price Comparison
Comparing the annual price of oral TDF/FTC vs. the dapivirine vaginal ring and injectable cabotegravir. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
HIV-Specific Neutralizing Antibodies by Target
A number of broadly neutralizing antibodies that target various regions of HIV’s Env protein are being developed for HIV prevention.
Broadly Neutralizing Antibody Combinations
Overview of the combinations of broadly neutralizing antibodies (bNAbs) under investigation in early clinical studies for HIV prevention.
Moving a Product to the Real World
The rollout of oral PrEP demonstrates that people don’t take PrEP simply because it’s available—there needs to be a demand for it, and it needs to be accessible, acceptable and used effectively by those who need and want it. These are the lessons the field is applying to the rollout of the dapivirine vaginal ring (DVR), and injectable cabotegravir (CAB) and lenacapavir (LEN) for PrEP. To reach the UNAIDS target of 10 million PrEP users by 2025, initiations of oral PrEP alone will not be enough—and this graphic shows that the field is beginning to apply past lessons to accelerate introduction of injectable PrEP options.
And for the latest on lenacapavir, visit here.
Preparing for LEN
Learning Lessons, Accelerating Access, Reducing Time to Impact
In the first year since efficacy results were reported, LEN for PrEP has achieved critical milestones in record time compared to oral PrEP, the dapivirine vaginal ring, and injectable cabotegravir. Speed, scale, and equity are still needed to deliver impact.
View the interactive version on our comprehensive page on all things lenacapavir. And the animated GIF version is available for download.
Source of Programmatic Cabotegravir for PrEP Supply
The first supplies of injectable cabotegravir for programmatic use (as opposed to use in implementation studies) began to arrive in countries in 2024. Currently, 16 countries are rolling out CAB for programmatic use, with the majority of supply provided by PEPFAR, and some additional quantities procured by the Global Fund.